ACLX
Arcellx, Inc. Healthcare - Biotechnology Investor Relations →
Arcellx, Inc. (ACLX) closed at $115.07 as of 2026-05-01, trading 102.1% above its 200-week moving average of $56.94. The stock is currently moving closer to the line, down from 103.7% last week. With a 14-week RSI of 91, ACLX is in overbought territory.
A big jump in activity this week — 2.3x the usual volume, and the price went up. Significantly more people than usual decided to buy. This kind of surge, especially on a stock already below its 200-week average, can be an early sign that sentiment is shifting.
In 173 weeks of available data, ACLX has never crossed below its 200-week moving average. This suggests the stock has maintained a strong long-term uptrend throughout its history.
With a market cap of $6.7 billion, ACLX is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -53.4%. The stock trades at 16.6x book value.
Share count has increased 31.3% over three years, indicating dilution.
Over the past 3.3 years, a hypothetical investment of $100 in ACLX would have grown to $352, compared to $184 for the S&P 500. That represents an annualized return of 45.9% vs 20.2% for the index — confirming ACLX as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ACLX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. ACLX currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from ACLX's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
ACLX has not crossed below its 200-week moving average in the available data (173 weeks).
Frequently Asked Questions
Is ACLX below its 200-week moving average?
No. Arcellx, Inc. (ACLX) is currently 102.1% above its 200-week moving average of $56.94. It would need to fall to $56.94 to cross below the line.
What is ACLX's 200-week moving average price?
Arcellx, Inc.'s 200-week moving average is $56.94 as of 2026-05-01. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
Is ACLX a good value right now?
Here's what our data says about ACLX as of 2026-05-01: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 91 (overbought). Free cash flow is currently negative. Return on equity is -53.4%. Price-to-book is 16.6x. This is not a buy or sell recommendation — always do your own research.
How does ACLX compare to the S&P 500?
Over the past 3.3 years, $100 invested in ACLX would have grown to $352, compared to $184 for the S&P 500. That's 45.9% annualized vs 20.2% for the index. ACLX has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-01